Tipifarnib Crystalline Forms Phase Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for preparing tipifarnib result in solid forms with low crystallinity and poor phase stability, lacking detailed characterization data, which are not suitable for pharmaceutical applications due to issues with morphology, stability, and physicochemical properties.
Innovation Solution
Development of new crystalline forms of tipifarnib, specifically Forms I, II, III, IV, and amorphous forms, with improved properties such as high crystallinity, stability, and reduced hygroscopicity, achieved through specific preparation methods involving solvents, crystallization processes, and drying conditions, as detailed by their X-ray powder diffraction patterns, DSC thermograms, and TGA analyses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If tipifarnib is prepared by conventional methods, then the preparation process is simple, but the crystallinity is low and phase stability is poor
Solution Approach 1:
The patent applies parameter changes by optimizing crystallization conditions including solvent selection (ethanol, isopropanol, acetonitrile, water), temperature control (4°C to 25°C), pH adjustment (using acetic acid or ammonia), and concentration ratios to transform tipifarnib into stable crystalline forms with defined XRPD patterns, thereby improving phase stability while maintaining manufacturing feasibility
Solution Approach 2:
The patent employs preliminary action by performing slurry treatment where tipifarnib is suspended in solvent, adjusted to specific pH, and incubated at controlled temperatures for defined periods (e.g., 1-24 hours) before final crystallization, ensuring the formation of stable crystalline forms with improved phase stability
2Manufacturing precision
If tipifarnib is prepared by conventional methods, then the manufacturing process is straightforward, but the crystallinity is low
Solution Approach 1:
The patent improves crystallinity by precisely controlling parameters including solvent type and volume ratio (1:1 to 1:10 drug-to-solvent), temperature (4°C to 25°C), pH (adjusted with acetic acid or ammonia), and incubation time (1-24 hours), resulting in crystalline forms with distinct XRPD patterns and high crystallinity
Solution Approach 2:
The patent employs preliminary slurry treatment where tipifarnib is suspended in solvent, adjusted to specific pH, and incubated at controlled temperatures for defined periods before final crystallization, ensuring the formation of highly crystalline products with well-defined diffraction patterns
3Ease of operation
If conventional tipifarnib forms are used, then no special preparation is needed, but hygroscopicity is high and processing characteristics are poor
Solution Approach 1:
The patent changes the physical form parameters of tipifarnib by controlling crystallization to produce Forms I-IV with different crystal structures, each exhibiting reduced hygroscopicity and improved processing characteristics such as flowability, compressibility, and morphology suitable for pharmaceutical manufacturing
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new crystalline forms exhibit enhanced stability, improved processing characteristics, and reduced hygroscopicity, ensuring better homogeneity and stability during drug manufacturing and storage, thus addressing the limitations of previous forms.
Implementation Method 1
using Cu-Kα radiation, the X-ray powder diffraction pattern of Form I, expressed as 2θ angles, has the following characteristic peaks: 8.4°±0.2°, 11.9°±0.2°, 16.4°±0.2°, 17.0°±0.2°, 18.5°±0.2° and 21.7°±0.2°
Implementation Method 2
DSC thermograms
Implementation Method 3
TGA analyses
Implementation Method 4
Development of new crystalline forms of tipifarnib, specifically Forms I, II, III, IV, and amorphous forms, with improved properties such as high crystallinity, stability, and reduced hygroscopicity, achieved through specific preparation methods involving solvents, crystallization processes, and drying conditions
Data Source
AI summary
The present invention relates to novel crystal forms of tipifarnib. Compared with the prior art, the crystal forms of tipifarnib have advantages in crystallinity, hygroscopicity, morphology, form stability and chemical stability. The present invention also relates to the preparation methods of crystal forms of tipifarnib, pharmaceutical composition thereof and their use in preparation for treating and/or preventing abnormal cell growth diseases.